Analyst Ryan Zimmerman of BTIG maintained a Buy rating on Alcon (ALC – Research Report), with a price target of $99.00.
Ryan Zimmerman has given his Buy rating due to a combination of factors surrounding Alcon’s recent financial performance and future outlook. The company reported strong net sales for the fourth quarter of 2024, surpassing both BTIG and Street estimates, particularly in the Surgical and Vision Care segments. This solid performance was driven by robust demand for consumables and contact lenses, along with new product innovations and strategic pricing.
Despite some headwinds from foreign exchange fluctuations impacting the fiscal year 2025 guidance, Alcon’s projected sales growth of 6%-8% is viewed positively. The company’s core operating margins and earnings per share are expected to remain strong, albeit slightly below current Street estimates. Overall, the healthy top-line growth and strategic initiatives in product development and pricing support Zimmerman’s confidence in Alcon’s stock potential.
Zimmerman covers the Healthcare sector, focusing on stocks such as Globus Medical, Glaukos, and GE Healthcare Technologies Inc. According to TipRanks, Zimmerman has an average return of -1.6% and a 44.38% success rate on recommended stocks.
In another report released yesterday, Needham also reiterated a Buy rating on the stock with a $106.00 price target.